OPKNasdaqPharmaceutical PreparationsFiscal year ends December 31
OPKO HEALTH, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q/A on Aug 28, 2026
$1.61+0.08 (+5.23%)
Close on Oct 19, 2026
- Market cap
- $1.22B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
33.9%
Operating margin
-19.3%−23.4 pts over 5 years
Net margin
-37.2%−39.3 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -14.9% | -15.5% | -15.8% | +2.1% | |
| Gross profit | -5.8% | -10.6% | – | -7.5% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -2.4% | 1.9% | -17.1% | |
| Return on assets | -1.7% | 1.3% | -10.9% | |
| Current ratio | 1.84 | 1.39 | 3.97 | |
| Debt to equity | 0.01 | 0.00 | 0.00 | |
| Net debt to EBITDA | -6241.40× | -0.48× | 13.98× | |
| Interest coverage | – | – | – | |
| Inventory turnover | 1.1× | – | 6.5× | |
| Capex to revenue | 1.7% | 2.3% | 2.0% | |
| Diluted shares | 556M | 641M | 751M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Opko Health generated $523.75M from operations and spent $247.56M on capital expenditure, dividends and share buybacks. 45% of that went back into the business.
Generated
$523.75M
Used
$247.56M
Capital expenditure$110.30M45%Dividends$00%Share buybacks$137.26M55%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-37.2%
×Asset turnover0.29×
×Equity multiplier1.57×
=Return on equity, FY2025-17.1%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -37.2% | 0.29× | 1.57× | -17.1% |
| FY2024 | -7.5% | 0.34× | 1.53× | -3.9% |
| FY2023 | -21.9% | 0.41× | 1.42× | -12.8% |
| FY2022 | -32.7% | 0.44× | 1.41× | -20.2% |
| FY2021 | -1.7% | 0.73× | 1.45× | -1.8% |
| FY2020 | 2.1% | 0.60× | 1.46× | 1.9% |
| FY2019 | -34.9% | 0.38× | 1.40× | -18.5% |
| FY2018 | -15.5% | 0.39× | 1.39× | -8.4% |
| FY2017 | -31.6% | 0.36× | 1.38× | -15.7% |
| FY2016 | -4.3% | 0.40× | 1.38× | -2.4% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$225.68M
- Cash generatingOperating cash flow above zero-$178.54M
- Return on assets improvedROA up on the prior year-2.6% → -10.3%
- Earnings backed by cashOperating cash flow above net income-$178.54M vs -$225.68M
- Less leverageLong-term debt to assets fell0.1% → 0.1%
- Better liquidityCurrent ratio rose3.43 → 3.97
- No dilutionShare count did not rise694M → 751M
- Gross margin improvedGross margin up on the prior year30.64% → 33.93%
- More efficientAsset turnover rose0.35 → 0.28